Dr Mark Wigglesworth

Mark Wigglesworth holds a BSc. degree in Neuroscience from Nottingham University and gained his PhD at Leeds University by completing a project on forced evolution. Since then he has worked for both GlaxoSmithKline and AstraZeneca, focusing on early stages of drug discovery, target validation and screening applications. He now leads AstraZeneca’s Global High Throughput Screening Centre and is an active member of the European Laboratory Research and Innovation Group (ELRIG) including co-director responsibility for their Research and Innovation conference. Mark has contributed to numerous publications in the field of GPCR pharmacology, hit identification and Compound Management including editing a book describing the Management of Biological and Chemical Samples for Screening Applications. In his current role he leads a team of more than 20 scientists dedicated to identifying novel chemical starting points for drug discovery programmes and maintains a collaborative interest in Synthetic Biology.